It is indeed remarkable that our pharmaceutical industry constantly complains about how cumbersome it is to get new methods and medications approved in Germany, when apparently it's much easier for foreign companies here. And it's quite outrageous, the whole thing.
But it's been a long time since it was about the patient in such matters, as shown by the increasingly exposed fraud schemes in recent times (Chinese dentures, inferior heart valves, ...)
So who ultimately pays the damage? We do. And then we're told that the healthcare system is unprofitable and we have to accept further service cuts while simultaneous premium increases.
I found the original article at Spiegel Online: Wissenschaft.